Recent advances in the diagnosis of heart failure

Current Cardiology Reports

Volumn 6, Issue 3, 2004, Pages 205-210

  O'Neill, James O ^b   Taylor, David O ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 1 RECEPTOR; MESSENGER RNA; NATRIURETIC PEPTIDE TYPE C; NEUROHORMONE; RELAXIN; UROTENSIN; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

CARDIOVASCULAR SYSTEM EXAMINATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIASTOLE; DISEASE CLASSIFICATION; DISEASE MARKER; DYSPNEA; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART ASSIST DEVICE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART SURGERY; HEART TRANSPLANTATION; HORMONE DETERMINATION; HUMAN; INTERMETHOD COMPARISON; KIDNEY BLOOD FLOW; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MORTALITY; PATIENT CARE; PREDICTION; PREVALENCE; REVIEW; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL; SYMPTOM; SYSTOLE; BLOOD; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TRENDS;

BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; SEVERITY OF ILLNESS INDEX;

EID: 3142775616     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0025-8     Document Type: Review

References (39)

1. Jessup M, Brozena S: Heart failure. N Engl J Med 2003, 348:2007-2018.
2. Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001, 104:2996-3007.
3. Stevenson LW, Perloff JK: The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989, 261:884-888.
4. Dao Q, Krishnaswamy P, Kazanegra R, et al: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001, 37:379-385.
5. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002, 105:1387-1393.
6. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment. Circulation 2002, 105:1503-1508.
7. Kawaguchi M, Hay I, Fetics B, Kass DA: Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107:714-720.
8. Zile MR: Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003, 41:1519-1522.
9. Zile MR, Gaasch WH, Carroll JD, et al.: Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001, 104:779-782.
10. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003, 362(9380):316-22.
11. Maisel AS, McCullough PA: Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 2003, 4(Suppl 4):S3-S12.
12. Lainchbury JG, Campbell E, Frampton CM, et al.: Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003, 42:728-735.
13. McCullough PA, Omland T, Maisel AS: B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003, 4:72-80.
14. Maisel AS, Krishnaswamy P, Nowak RM, et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
15. Harrison A, Morrison LK, Krishnaswamy P, et al.: B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002, 39:131-138.
16. Berger R, Huelsman M, Strecker K, et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 105:2392-2397.
17. Muller C: Brain natriuretic peptide for Acute Shortness of breath EvaLuation: a randomized comparison (BASEL). Vienna: European Society of Cardiology; 2003.
18. Maisel A: Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter trial examining BNP levels, emergency physician decision-making and outcomes in patients presenting with shortness of breath. Presented at the 7th annual Heart Failure Society of America Meeting. Las Vegas, NV; September 21-24, 2003.
19. Troughton RW, Frampton CM, Yandle TG, et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
20. Tang WH GJ, Lee MJ, Starling RC, et al.: Plasma B-type natriuretic peptide levels in ambulatory patients with established symptomatic systolic heart failure. Circulation 2003, 108:2964-2966.
21. Kazanegra R, Cheng V, Garcia A, et al.: A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001, 7:21-29.
22. O'Neill JO, McRae AT, Troughton RW, et al.: Brain natriuretic peptide levels do not correlate with acute cellular rejection in de novo orthotopic heart transplant recipients. J Heart Lung Transplant 2004, in press.
23. O'Neill JO, McRae AT III, Troughton RW, et al.: B-type natriuretic peptide levels are not a surrogate marker for invasive haemodynamics during management of patients with severe heart failure. Circulation 2003, 108(Suppl IV):557.
24. Sim V, Hampton D, Phillips C, et al.: The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction- cost-effectiveness in relation to open access echocardiography. Fam Pract 2003, 20:570-574.
25. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ: Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003, 41:113-120.
26. Vasan RS, Benjamin EJ, Larson MG, et al.: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002, 288:1252-1259.
27. Wright S, Doughty RN, Pearl,A, et al.: Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart failure diagnosis in primary care. J Am Coll Cardiol 2003, 42:1793-1800.
28. Suzuki T, Hayashi D, Yamazaki T, et al.: Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998, 136:362-363.
29. Hayakawa H, Komada Y, Hirayama M, et al.: Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001, 37:4-9.
30. Nousiainen T, Vanninen E, Jantunen E, et al.: Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002, 251:228-234.
31. Weinberg EO, Shimpo M, Hurwitz S, et al.: Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
32. Dschietzig T, Richter C, Bartsch C, et al.: The pregnancy hormone relaxin is a player in human heart failure. Faseb J 2001, 15:2187-2195.
33. Fisher C, Berry C, Blue L, et al.: N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003, 89:879-881.
34. Dschietzig T, Bartsch C, Richter C, et al.: Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 2003, 92:32-40.
35. Ng LL, Geeranavar S, Jennings SC, et al.: Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Land) 2004, 106:129-133.
36. Richards AM, Nicholls MG, Lainchbury JG, et al.: Plasma urotensin II in heart failure. Lancet 2002, 360:545-546.
37. Russell FD, Meyers D, Galbraith AJ, et al.: Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003, 285:H1576-1581.
38. Ng LL, Loke I, O'Brien RJ, et al.: Plasma urotensin in human systolic heart failure. Circulation 2002, 106:2877-2880.
39. Nicholls MG, Charles CJ, Lainchbury JG, et al.: Adrenomedullin in heart failure. Hypertens Res 2003, 26(Suppl):S135-S140.